Investigating molecular, genetic and epigenetic mechanisms of treatment resistance in human tumors and to devise strategies to overcome
Dr. Chakravarti’s research group contains multiple faculty members and has a primary focus of investigating the molecular, genetic and epigenetic mechanisms of treatment resistance in human tumors and of developing strategies to circumvent this resistance in the clinic. A major focus is on signal transduction pathways, specifically the PI3K/AKT pathway in glioblastoma and prostate cancer.
Dr. Chakravarti is an internationally recognized cancer researcher and has received continuous federal funding since 1999 to support his research activities. He currently serves as chair of the RTOG Brain Tumor Translational Research Group and co-chair of the clinical RTOG Brain Tumor Committee. Further, he is the United States delegate on the EORTC Brain Tumor Steering Committee. Dr. Chakravarti is a standing member of the NIH Cancer Biomarkers Study Section (CBSS) and serves on NIH PO1 and SPORE review panels. He has served on national panels that have determined directions and indications of targeted therapies. For his accomplishments, Dr. Chakravarti has been recognized as a fellow of the American College of Radiation Oncology.
His research team has uncovered therapeutic targets in various tumors, such as human gliomas, that have led to important international clinical studies of novel targeted therapy agents. Further, Dr. Chakravarti’s team has identified prognostic and predictive biomarkers in various cancers that have led to revised molecular-based classification schemes for certain tumors, such as human glioblastomas (GBMs).
His team is conducting high-throughput molecular, genetic and epigenetic profiling of brain tumors, prostate cancer, bladder cancer and melanomas. The correlative approach is genome-wide, including techniques such as SNP, miRNA and global methylation analyses, to identify molecular prognostic and predictive biomarkers.
Additional research topics include glioma stem cells, DNA repair pathways, tumor microenvironment and cell metabolism. Other disease investigational sites include melanoma, bladder, gastrointestinal and lung cancer.
Erica Hlavin Bell, PhD – Cancer biomarkers; DNA repair; radiobiology
Naduparambil Jacob, PhD – Biomarkers of radiation injury; bioterrorism; chromatin and DNA repair; targeting Chromosomal Passenger Complex (CPC) in solid tumors; cancer chemoprevention
Tim Lautenschlaeger, MD – Signal transduction; cancer biomarker discovery; experimental therapeutics in cancer; radiation oncology
Kamalakannan Palanichamy, PhD – Glioma stem cells; radiation and drug resistance, signal transduction, integrative OMICS
Meng Xu Welliver, MD, PhD – Cell metabolism; radiobiology
Terrence Williams, MD, PhD – Radiation and chemotherapy resistance; cellular and DNA response to radiation; biologic markers for therapeutic response; role of stroma in radiation response; molecular imaging